Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Shire serves as an industry leader in research and treatments of rare and orphan diseases, allowing patients with severe conditions to lead better lives. The company’s deep understanding of patients and their needs enables them to develop and deliver health care in therapeutic areas including, behavioral disorders and gastrointestinal diseases, as well as other symptomatic conditions followed by specialists. Shire upholds an ambition to imagine the future and be at the forefront of health care in creating value for patients, physicians, policymakers, payers and shareholders. Shire France is the French subsidiary of Shire Pharmaceuticals Group plc based in the UK and the US. As the operator of specialty pharmaceuticals and as such, its products are sold by the conventional circuit of distribution: custodians, distributors, pharmaceutical wholesale distributors, pharmacies, care facilities. The French affiliate specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, genetic diseases.
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership…
US pharmaceutical companies have long been in the French market but in your experience how do you feel they have integrated the differences in culture? Is this a finished topic…
See our Cookie Privacy Policy Here
